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Abstract
The filoviruses, Marburg virus and Ebola virus, cause severe hemorrhagic fever with high mortality in humans and
nonhuman primates. Among the most promising filovirus vaccines under development is a system based on recombinant
vesicular stomatitis virus (rVSV) that expresses an individual filovirus glycoprotein (GP) in place of the VSV glycoprotein (G).
The main concern with all replication-competent vaccines, including the rVSV filovirus GP vectors, is their safety. To address
this concern, we performed a neurovirulence study using 21 cynomolgus macaques where the vaccines were administered
intrathalamically. Seven animals received a rVSV vector expressing the Zaire ebolavirus (ZEBOV) GP; seven animals received a
rVSV vector expressing the Lake Victoria marburgvirus (MARV) GP; three animals received rVSV-wild type (wt) vector, and
four animals received vehicle control. Two of three animals given rVSV-wt showed severe neurological symptoms whereas
animals receiving vehicle control, rVSV-ZEBOV-GP, or rVSV-MARV-GP did not develop these symptoms. Histological analysis
revealed major lesions in neural tissues of all three rVSV-wt animals; however, no significant lesions were observed in any
animals from the filovirus vaccine or vehicle control groups. These data strongly suggest that rVSV filovirus GP vaccine
vectors lack the neurovirulence properties associated with the rVSV-wt parent vector and support their further development
as a vaccine platform for human use.
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Introduction
The order Mononegavirales comprises the non-segmented, negative
sense, single-stranded RNA viruses in the family Filoviridae along
with the families Rhabdoviridae, Paramyxoviridae,a n dBornaviridae. The
family Filoviridae contains two genera, Ebolavirus (EBOV) and
Marburgvirus (MARV) [1,2]. Infection with EBOV or MARV causes
severe and often fatal hemorrhagic fever (HF) with case fatality rates
ranging from 23–90% depending on the strain and/or species. The
Ebolavirus genus is diverse and consists of four species: Sudan ebolavirus
(SEBOV), Zaire ebolavirus (ZEBOV), Cote d’Ivoire ebolavirus (CIEBOV),
and Reston ebolavirus (REBOV). A putative fifth species, Bundibugyo
ebolavirus (BEBOV) was discovered during an outbreak in Uganda
during 2007 [3]. Together, the Ebolavirus genus has accounted for at
least 22 outbreaks dating back to 1976 with18 of these occurring
within the last 20 years [4]. The Marburgvirus genus has one species,
Lake Victoria marburgvirus, that has been responsible for at least nine
outbreaks since 1967 with five of these occurring in the last decade
[4].The increasedfrequencyofEBOV and MARV outbreaksalong
with the fact that these viruses are potential agents of bioterrorism
has increased public health concern regarding filoviruses. Presently,
there are no licensed vaccines or postexposure treatments available
for human use; however, there are at least six different vaccine
candidates that have shown the potential to protect nonhuman
primates (NHP) from lethal EBOV and/or MARV infection
[5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20].
The filoviruses contain an RNA genome, approximately 19 Kb
in length, which encodes seven proteins that are arranged from 39
to 59: nucleoprotein (NP); virion protein (VP)35; VP40; glycopro-
tein (GP); VP30; VP24; and the polymerase protein (L). The
EBOV species express two extra nonstructural proteins from the
GP gene referred to as soluble (s)GP [2] and small soluble (ss)GP
[21]. Vaccine studies that have shown protection in animals from
filovirus infections have primarily employed the GP protein as the
immunogen with a few studies also using VP40 and/or NP
[5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20].
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Rhabdoviridae, is composed of a genome of approximately 11 Kb
which encodes five proteins that are arranged from 39 to 59:
nucleoprotein (N), phosphoprotein (P), matrix protein (M),
glycoprotein (G), and the large catalytic subunit (L) of the RNA-
dependent RNA polymerase. Over the last decade the use of
recombinant (r)VSVs as vaccine candidates has been studied due
to the ability to insert and express foreign genes in the simple
genome, the ability to propagate the virus to high titers in most
mammalian cell lines, the lack of recombination or insertion into
the host cell genome, the extremely low percentage of VSV
seropositivity in the general population of Central America
[22,23], and the minimal pathogenicity of VSV in humans. rVSV
vectors have been developed as vaccine candidates against many
important human pathogens such as influenza virus [24], human
immunodeficiency virus (HIV) [25,26,27], measles virus [28,29],
respiratory syncytial virus [30], papillomavirus [31,32], severe
acute respiratory syndrome coronavirus [33], and HF viruses such
as Lassa, EBOV, and MARV [34].
The rVSV filovirus GP vaccine platform, where the VSV
glycoprotein (G) is replaced with filovirus GP, has shown promise
as both a single-injection preventive vaccine [8,9,11,12,18,35] and
a postexposure treatment against EBOV and/or MARV challenge
in NHPs [36,37,38,39]. Initial studies showed that a single
intramuscular (i.m.) vaccination of cynomolgus macaques with a
rVSV vector expressing the ZEBOV GP or MARV GP induced
strong humoral and/or cellular immune responses and elicited
complete protection against a high dose (1000 plaque forming unit
[PFU]) i.m. challenge of homologous ZEBOV or MARV given 28
days later [8]. The efficacy of these vaccines to protect by i.m.
vaccination against homologous high dose (1000 PFU) aerosol
challenge was also tested. Importantly, homologous aerosol
challenge with either ZEBOV or MARV 28 days after vaccination
resulted in complete protection of the macaques [11]. In addition
to vaccinating via the i.m. route, the ability of the rVSV-ZEBOV-
GP vaccine to protect cynomolgus macaques by intranasal and
oral routes was also studied [18]. Vaccination by these different
routes resulted in complete protection against homologous
challenge and elicited robust ZEBOV GP-specific humoral
responses and T-cell responses that were induced after vaccination
and also 6 months after ZEBOV challenge [18]. More recently, we
showed that a single injection of a blended vaccine consisting of
equal parts of rVSV-ZEBOV-GP, rVSV-SEBOV-GP, and rVSV-
MARV-GP completely protected NHPs against lethal challenge
with either ZEBOV, SEBOV, CIEBOV, or MARV [12].
While the rVSV filovirus GP vectors have proven robust as
preventive vaccines, these vectors have also shown utility as
postexposure treatments with the rVSV-MARV-GP vector
protecting 100%, 83%, and 33% of rhesus macaques challenged
with MARV and treated 30 minutes, 24 hours, and 48 hours
postexposure, respectively [36,39]. Treatment of macaques
30 minutes after challenge with a rVSV-SEBOV GP vector
protected all animals against a lethal SEBOV challenge [38] while
treatment of macaques 30 minutes after challenge with the rVSV-
ZEBOV GP vector protected 50% of the animals against a
homologous ZEBOV challenge [37].
To date, the rVSV filovirus GP vectors have been used in over
80 NHPs with no signs of toxicity as a result of vaccination
[8,9,11,12,18,35]. In addition, the rVSV-ZEBOV-GP vector was
recently used as a treatment less than 48 hours after a possible,
accidental ZEBOV exposure to a laboratory worker in Germany.
While the efficacy of the treatment was not conclusive, the treated
individual experienced mild fever, myalgia, and headache
12 hours after injection [40]. Although these data suggest that
the vectors are innocuous, the use of the rVSV filovirus GP vectors
as vaccines and/or postexposure treatments in humans requires
further safety testing. This is important considering that the
vaccine is replication-competent and there is potential for VSV
neurovirulence (NV), as has been reported in rodents
[41,42,43,44,45,46,47,48], macaques [49], cattle, sheep, and
horses [50]. Regardless of the potential for rVSV vector NV,
replication-competent vaccines that are to be used in humans are
generally subjected to NV testing. Typically, NV is evaluated by
direct inoculation of the vaccine into the central nervous system
(CNS) of a NHP. These NV tests have been developed for measles
virus [51,52], mumps virus [53,54], yellow fever virus [55,56], and
poliovirus [57,58]. Most recently rVSV HIV vaccine variants have
been tested for NV by intrathalamic (IT) inoculation with
promising results [59].
In the current study, we evaluated the NV potential of the
rVSV-ZEBOV-GP and the rVSV-MARV-GP vectors in cyno-
molgus macaques. The NV tests were modeled on previous
examinations of the yellow fever virus vaccine [55] and rVSV HIV
vector variants [59] where cynomolgus macaques were given an
IT inoculation with 10
7 PFU of the vaccine and closely monitored
over the course of 21 days.
Materials and Methods
rVSV vectors
The rVSV-wt (Fig. 1A) used in this study was recovered from
cDNA using methods previously described [60]. The rVSV
filovirus GP vectors, rVSV-ZEBOV-GP (Fig. 1A) and rVSV-
MARV-GP (Fig. 1A) were recovered from cDNA as previously
described [34]. All viruses were propagated by infecting Vero cells
at a multiplicity of infection of 0.01 and collecting supernatants
when cells showed cytopathic effects. Media used for propagating
the rVSVs consisted of Dulbecco’s Modified Essential Media, 10%
heat-inactivated certified FBS (Invitrogen, Carlsbad, CA), 16
penicillin/streptomycin (Invitrogen), and 16 Glutamax (Invitro-
gen) (D-10). Virus supernatants or mock-infected cell supernatants
(vehicle control) were clarified of cell debris and aliquoted for use
in the study and titers determined on Vero cell monolayers by
conventional plaque assay.
Author Summary
Ebola and Marburg viruses are categorized as Category A
priority pathogens by several US Government agencies as
a result of their high mortality rates and potential for use
as agents of bioterrorism. There are currently no vaccines
or therapeutics approved for human use. A replication-
competent, recombinant vesicular stomatitis virus (rVSV)
vector expressing filovirus glycoproteins (GP), in place of
the VSV G protein has shown promise in lethal nonhuman
primate models of filovirus infection as both a single-
injection preventive vaccine and a postexposure treat-
ment. Replication-competent vaccines that are intended
for use in humans usually undergo neurovirulence testing
as was done for measles virus, mumps virus, yellow fever
virus, and poliovirus vaccines. Here we used a conventional
neurovirulence test to evaluate the safety of our rVSV-
based Zaire ebolavirus and Lake Victoria marburgvirus GP
vaccines in cynomolgus macaques. Importantly, we
demonstrate for the first time that these rVSV filovirus
GP vectors lack neurovirulence when compared to a rVSV
wild-type vector.
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endotoxin using The EndosafeH-Portable Test System (PTS)
(Charles River, Wilmington, MA). Virus preparations were diluted
1:100 in Limulus Amebocyte Lysate (LAL) Reagent Water (LRW)
per manufacturer’s directions and endotoxin levels were tested in
LAL EndosafeH-PTS cartridges as directed by the manufacturer.
Each virus preparation was found to be below detectable limits
while positive controls showed that the tests were valid.
Animals
A total of 21 healthy male cynomolgus macaques (Macaca
fascicularis) (4–7 Kg) were purchased from Charles River Labora-
tories (Wilmington, MA). All animals ranged in age from 4 to 6
years with the exception of two animals (67-01, 68-01) which were
18 years in age. The study was conducted at the New England
Primate Research Center (NEPRC), Harvard Medical School and
the animals were given care in accordance with standards of the
Association for Assessment and Accreditation of Laboratory
Animal Care and the Harvard Medical School Animal Care
and Use Committee. All animal work adhered to the regulations
outlined in the USDA Animal Welfare Act (9 CFR, Parts 1, 2, and
3) and the conditions specified in the Guide for the Care and Use
of Laboratory Animals (ILAR publication, 1996, National
Academy Press) and by the Harvard Medical School Animal
Care and Use Committee. These experiments and procedures
were approved by the Harvard Medical Area Standing Committee
on Animals. Any clinical signs of illness or distress were promptly
reported to the responsible veterinarian, who recommended
treatment for minor ailments or euthanasia when clinical
observations and neurological scores of animals reached levels
based on the approved Harvard Medical School Animal Care and
Use Committee protocol.
Inoculation procedures
Animals were sedated with Ketamine HCl administered i.m.,
intubated, and placed on O2/Isoflurane. A saphenous catheter
was placed and NaCl infused at 10 ml/hr. Atropine, Buprenex,
and Cephazolin were administered i.m. The animals head was
shaved and surgically prepared. A midline incision was made
along the scalp and the skin and musculature was retracted. Two
0.16 cm holes (one per side) corresponding to the positioned
incisions on the left and right sides were made through the skull
using a high speed general twist drill. Sterile saline was used to
flush and clear bony debris during drilling. The inoculum was
administered using a 25 gauge, 1.5 inch needle into the thalamic
region. Animals received one of four possible inoculates: the three
primary inoculates consisted of 1610
7 PFU of either rVSV-wt
(n=3), rVSV-ZEBOV-GP (n=7), or rVSV-MARV-GP (n=7) in
150 ml of 10% heat-inactivated fetal bovine serum (FBS) in
Dulbecco’s modified Eagle media. The vehicle control (n=4)
consisted of clarified Vero cell culture supernatant that was 10%
heat-inactivated FBS in Dulbecco’s modified Eagle media. A small
piece of gel foam was placed in the burr hole and direct pressure
was used to achieve hemostasis. The musculature and skin were
closed in a simple interrupted pattern. Cephazolin was adminis-
tered for 5 days and Buprenex was administered for 48 hours post
procedure (or longer if necessary). The animals were monitored
daily by both the veterinary and animal care staff. Each animal
was given a thorough physical examination at the time of
scheduled phlebotomy. Blood from phlebotomies was monitored
Figure 1. Neurovirulence assay design. (A) Illustration of the rVSV genomes used in the IT inoculation procedures. Note that the only difference
between the rVSV vectors used in this study were the glycoproteins. (B) Schematic of the sampling days during the 21 day study. S=swab, B=blood,
N=necropsy, * day 5 necropsy of 67-01, ** day 6 necropsy of 56-09.
doi:10.1371/journal.pntd.0001567.g001
VSV-Based Filovirus Vaccines Lack Neurovirulence
www.plosntds.org 3 March 2012 | Volume 6 | Issue 3 | e1567for hematology from whole blood and clinical chemistry from
serum. Daily cage side neurological exams were conducted. Each
animal received an overall impairment score (0–4) and were
further characterized neurologically based on specific observation
points listed: 0=No clinical signs of encephalitis; 1=Rough coat,
not eating; 2=High pitch vocalization, inactive, slow moving;
3=Shaky movements, tremors, incoordination, limb weakness;
4=Inability to stand, limb paralysis, moribund.
Hematology and serum biochemistry
Total white blood cell counts, white blood cell differentials, red
blood cell counts, platelet counts, hematocrit values, mean cell
volume, mean corpuscular volume, and mean corpuscular hemo-
globin concentrationweredetermined from blood samples collected
in tubes containing EDTA, using a laser-based hematologic
analyzer (Hemavet, Drew Scientific, Waterbury, CT). Concentra-
tions of albumin, amylase, globulin, alanine aminotransferase,
aspartate aminotransferase, alkaline phosphatase, gamma-gluta-
myltransferase, lactate dehydrogenase, glucose, cholesterol, total
protein, total bilirubin, direct bilirubin, urea nitrogen, creatinine,
creatinine kinase, triglyceride, bicarbonate, calcium, phosphorus,
chloride, potassium, and sodium were measured by IDEXX
VetConnect (Westbrook, ME) using an Olympus AU5421 bio-
chemistry analyzer (Olympus Americas, Center Valley, PA).
Table 1. Daily and group mean neurologic scores of animals
inoculated IT.
Group Animal # Clinical Scores
Daily Mean Group Mean
Vehicle Control 53-09 0 0
60-09 0
68-01 0
359-09 0
rVSV-wt 56-09* 2.8 2
67-01** 3.2
362-09 0
rVSV-ZEBOV-GP 352-09 0 0
354-09 0
357-09 0
358-09 0
360-09 0
361-09 0
363-09 0
rVSV-MARV-GP 52-09 0 0
57-09 0
59-09 0
61-09 0
355-09 0
356-09 0
364-09 0
0=No clinical signs of encephalitis; 1=Rough coat, not eating; 2=High pitch
vocalization, inactive, slow moving; 3=Shaky movements, tremors,
incoordination, limb weakness; 4=Inability to stand, limb paralysis, moribund.
*56-09 was euthanized at day 6 post inoculation with a clinical score of 3. The
animal was assigned a clinical score of 4 for the remainder of the 21 day
experimental period.
**67-01 was euthanized at day 5 post inoculation with a clinical score of 3. The
animal was assigned a clinical score of 4 for the remainder of the 21 day
experimental period.
doi:10.1371/journal.pntd.0001567.t001
Table 2. Viral loads in neural tissue and LN as measured by
qRT-PCR (log10 copies/g)/or virus log10.
Group Animal #FC-L OC-L FC-R OC-R CSC LN
Vehicle Control 53-09 neg@ neg neg neg neg neg
60-09 neg neg neg neg neg neg
68-01 neg neg neg neg neg neg
359-09 neg neg neg neg neg neg
rVSV-wt 56-09* 7.8/4.5 neg 7/4.2 neg neg neg
67-01** 7.2/4.1 neg neg neg neg neg
362-09 neg neg neg neg neg neg
rVSV-ZEBOV-GP 352-09 neg neg neg neg neg neg
354-09 neg neg neg neg neg neg
357-09 neg neg neg neg neg neg
358-09 4.2/0 neg neg neg neg neg
360-09 neg neg neg neg neg neg
361-09 neg neg neg neg neg neg
363-09 neg neg neg neg neg neg
rVSV-MARV-GP 52-09 neg neg neg neg neg neg
57-09 neg neg neg neg neg neg
59-09 neg neg neg neg neg neg
61-09 neg neg neg neg neg 5.4/0
355-09 neg neg neg neg neg neg
356-09 neg neg neg neg neg neg
364-09 neg neg neg neg neg neg
@Negative (neg) result below the detection of assay at 4 log10 copies/g of
tissue. FC-L=left frontal cortex, OC-L=left occipital cortex, FC-R=right occipital
cortex, OC-R=right, occipital cortex, CSC=cervical spinal cord, LN=lymph
node; rVSV vaccine inoculation occurred in left hemisphere.
*euthanized on day 6;
**euthanized on day.
doi:10.1371/journal.pntd.0001567.t002
Table 3. Virus and Virus anti/genomes in animal swabs as
measured by virus isolation and qRT-PCR.
Day/Animal #/Virus isolation log10
Group No. Positive Nasal Oral Rectal
Vehicle Control 0
A neg@ neg neg
rVSV-wt 0
B neg neg neg
rVSV-ZEBOV-GP 3
C 7
+++/352-09/0
2
++/357-09/3.3
21/358-09/0 14
++/358-09/0
rVSV-MARV-GP 0
D neg neg Neg
@Negative (neg) result below the detection of assay at 4 log10 copies/g of
tissue. 21=.4 log10 copies/swab,
++=5 log10 copies/swab,
+++=.6 log10 copies/swab.
doi:10.1371/journal.pntd.0001567.t003
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Animals were euthanized if neurologic signs developed or at the
scheduled study end-point, 21 days post inoculation, with an
overdose of intravenous sodium pentobarbital and necropsied
immediately afterward. Tissues from five brain regions (frontal
cortex (FC), occipital cortex (OC), cerebellum (CB), thalamus
(TH), and basal ganglia (BG) and three spinal cord (SC) regions
(cervical, thoracic, and lumbar) were collected in 10% neutral-
buffered formalin. Following one week fixation, the brain was
hemisectioned into right and left hemispheres and specified brain
regions were trimmed and embedded in paraffin, sectioned at
5 mm, and stained using hematoxylin and eosin (H&E).
Histopathologic analysis and scoring
H&E stained sections of brain and spinal cord were analyzed for
histopathologic changes associated with NV. For each animal,
sections of FC, BG, OC, TH, CB, brain stem (BS), and SC were
analyzed.Histopathologicchangesconsistent withNVweredouble-
blind scored based on presence and severity of perivascular
infiltrates, gliosis, neurodegeneration, satellitosis, and necrosis.
Cumulative assessment of all changes was scored on a severity
scale of 0–4 based on previously published work [59]: 0=no lesions;
1=minimal perivascular inflammatory infiltrate, no gliosis, no
neurodegeneration, no satellitosis, and no necrosis; 2=mild
perivascular inflammatory infiltrate, mild gliosis, no neurodegener-
ation, no satellitosis, and no necrosis; 3=moderate inflammatory
infiltrate with moderate gliosis, mild neurodegeneration, mild
satellitosis, and mild necrosis; and 4=severe inflammatory infiltrate
with moderate to severe gliosis, neurodegeneration, satellitosis, and
necrosis.Scoresforbrainregionswerederived forbothrightand left
hemispheres and also combined for total NV.Scores for SC sections
were collectively represented as a single number. Statistics were
calculated for histology scores using GraphPad Prism 5 software by
using an unpaired, two-tailed, t test.
rVSV TaqMan PCR assay
To assess the viral loads in nasal, oral, and rectal swabs (day 0,
2, 4, 7, 14, and 21), blood (day 0, 2, 4, 7, 14, and 21), tissues
(spleen, liver, kidney, heart, axillary lymph node, and adrenal
gland), and neural tissues (FC, BG, OC, TH, CB, BS, and SC)
RNA was extracted from swabs (Virus RNA kit, Qiagen, Valencia,
CA) and tissue sections (RNeasy kit, Qiagen) and TaqMan PCR
for the rVSV genome was performed. The rVSV TaqMan assay
for detecting VSV genomes and antigenomes was developed using
primers and a probe that target the intergenic region (between M
and G on the VSV genome) and the M gene as previously
described [61]. The rVSV M probe primer (Applied Biosystems,
Carlsbad, CA) had the sequence 6-carboxyfluorescein (6FAM)-59
TTGGCCTGATTGTCG 39-6 carboxytetramethylrhodamine
(TAMRA). One-step real-time PCR (RT-PCR) was done using
OneStep RT-PCR kits (Qiagen). All RT-PCR mixtures contained
5 ml of RNA eluate and master mixes were set up following the
Figure 2. Representative vehicle control histology with no lesions in the neural tissue. (A) Frontal cortex (106). (B) Basal ganglia (106). (C)
Cerebellum (106). (D) Spinal Cord (Asterisk denotes central canal) (106).
doi:10.1371/journal.pntd.0001567.g002
VSV-Based Filovirus Vaccines Lack Neurovirulence
www.plosntds.org 5 March 2012 | Volume 6 | Issue 3 | e1567manufacturer’s protocols. Standards and test samples were assayed
in triplicate using the CFX96 detection system (Bio-Rad
Laboratories, Hercules, CA) with the following cycle conditions:
50uC for 10 min, 95uC for 5 min, and 40 cycles of 95uC for 10 s
and 60uC for 30 s. Threshold cycle (CT) values representing rVSV
genomes and antigenomes were analyzed with CFX Manager
Software, and data are shown as log10 genome equivalents (GEq).
To create the GEq standard, RNA from rVSV-wt stocks was
extracted and the number of rVSV genomes was calculated using
Avogadro’s number and the molecular weight of the rVSV
genome [61].
rVSV isolation
To assess if there was replicating virus in nasal, oral, and rectal
swabs (day 0, 2, 4, 7, 14, and 21), blood (day 0, 2, 4, 7, 14, and 21),
non-neural tissues (spleen, liver, kidney, heart, axillary lymph
node, and adrenal gland), and neural tissues (FC, BG, OC, TH,
CB, BS, and SC) virus titers were determined by conventional
plaque assay on Vero cell monolayers. Swabs were collected and
placed in D-10 media, while tissues were placed in D-10 media
and then homogenized before plaque assay.
Results
Clinical observations
In order to evaluate the NV potential of the rVSV filovirus GP
vectors cynomolgus macaques were inoculated by IT inoculation
with 1610
7 PFU of either rVSV-ZEBOV-GP (n=7, Fig. 1A),
rVSV-MARV-GP (n=7, Fig. 1A), rVSV-wt (n=3, Fig. 1A), or
vehicle control (n=4). Each animal received two inoculations, one
per hemisphere, with the left hemisphere receiving the experi-
mental inoculation and the right hemisphere receiving the vehicle
control. Animals were then observed for neurologic signs of
disease. Clinically, two macaques from the rVSV-wt control group
(67-01 and 56-09) developed progressive neurological signs
including ataxia, proprioceptive deficits, and tremors, and were
euthanized at either day 5 or 6 post inoculation (Table 1). One of
the rVSV-wt animals (362-09) did not show any discernable
neurological signs. No neurological deficits were observed in any
of the macaques in the vehicle control, rVSV-ZEBOV-GP, or
rVSV-MARV-GP groups. Hematology and serum biochemistry
were also monitored for each animal with no changes being
observed in any animal, when compared to a prebleed for each
animal, over the course of the study (data not shown).
Detection of rVSV and rVSV RNA in swabs, blood, and
tissues
Swabs and blood collected over the 21 day study (Fig. 1B), and
tissues collected at necropsy were prepared for virus and RNA
isolation to detect rVSV by plaque assay and rVSV genomic and
antigenomic RNA by TaqMan quantitative real-time (qRT)-PCR
as an indicator of rVSV replication. The two rVSV-wt macaques
that showed clinical signs of neurologic disease (Table 1) also had
rVSV and rVSV genome in the frontal cortex sections with one
animal (56-09) having both rVSV and rVSV genome in the left
and right hemisphere frontal cortex sections (Table 2). One animal
from the rVSV-ZEBOV-GP group (358-09) had low levels of
rVSV RNA detectable at day 21 post inoculation but no virus was
isolated from the tissues (Table 2), while an animal from the rVSV-
MARV-GP group (61-09) had low levels of detectable rVSV RNA
in axillary lymph node (LN) taken at day 21 post inoculation with
no virus isolated from this tissue (Table 2). None of the other
macaques had detectable rVSV RNA in neural tissues, spleen,
liver, heart, kidney, axillary LN, or adrenal gland (data not shown
for non-neural negative tissues). Three animals from the rVSV-
ZEBOV-GP group also had detectable rVSV RNA in nasal (357-
09), oral (358-09), and rectal (352-09, 358-09) swabs at different
times post inoculation with only 357-09 having virus isolated from
the nasal swab at day 2 post inoculation (Table 3). None of the
animals had detectable levels of rVSV RNA in any blood samples
taken (data not shown).
Histopathological examination of brain and spinal cord
The four macaques that received the vehicle control IT in both
hemispheres had no inflammatory lesions in any of the brain or
spinal cord sections (Fig. 2, Table 4) examined except for one
section from one animal (359-09), which had a single meningeal
and parenchymal perivascular cuff of lymphocytes in the right
thalamus near the vehicle control inoculation site (Table 4).
The three macaques that received rVSV-wt had the most
profound histologic lesions (Table 4). Lesions were most
pronounced in the cortices and the basal ganglia, with lesions of
lesser severity encountered in the caudal brainstem and cerebel-
lum. Lesions consisted of marked perivascular cuffs and paren-
chymal aggregates of lymphocytes, macrophages, and fewer
plasma cells (Fig. 3, arrows and panels E and F). Lymphocytes
Table 4. Histopathological scores from left/right hemisphere
of the brain and spinal cord.
Group Animal # Day PI FC BG TH OC CB/BS SC
Vehicle Control 53-09 21 0/0 0/0 0/0 0/0 0/0 0
60-09 21 0/0 0/0 0/0 0/0 0/0 0
68-01 21 0/0 0/0 0/0 0/0 0/0 0
359-09 21 0/0 0/0 0/0 0/0 0/0 0
rVSV-wt 56-09* 6 4/4 4/4 3/2 1/1 2/2 3
67-01** 5 2/3 2/1 0/0 0/0 0/1 1
362-09 21 4/1 1/1 1/1 0/0 0/2 3
rVSV-ZEBOV-GP 352-09 21 1/1 1/0 1/0 0/0 0/0 0
354-09 21 1/1 0/0 1/0 0/0 0/0 0
357-09 21 1/0 0/0 0/0 0/0 1/0 0
358-09 21 0/0 1/0 1/0 0/1 0/0 0
360-09 21 1/0 0/0 0/0 0/0 0/0 0
361-09 21 1/0 0/0 0/0 0/0 0/0 0
363-09 21 0/0 0/0 0/0 0/0 0/0 0
rVSV-MARV-GP 52-09 21 0/1 1/0 1/0 0/0 0/0 0
57-09 21 0/0 0/0 0/0 0/0 0/0 0
59-09 21 1/0 0/0 1/0 0/0 0/0 0
61-09 21 0/0 0/0 0/0 0/0 0/0 0
355-09 21 1/0 1/4 0/0 0/0 0/0 0
356-09 21 1/1 0/0 0/0 0/0 0/0 0
364-09 21 1/0 0/0 0/1 0/0 0/1 0
Left score #/Right score #; Scores; 0=no lesions, 1=minimal perivascular
inflammatory infiltrate, no gliosis, no neurodegeneration, no satellitosis, and no
necrosis, 2=mild perivascular inflammatory infiltrate, mild gliosis, no
neurodegeneration, no satellitosis, and no necrosis, 3=moderate inflammatory
infiltrate with moderate gliosis, mild neurodegeneration, mild satellitosis, and
mild necrosis, and 4=severe inflammatory infiltrate with moderate to severe
gliosis, neurodegeneration, satellitosis, and necrosis.
FC=frontal cortex, BG=basal ganglia, TH=thalamus, OC=occipital cortex, CB/
BS=cerebellum/brain stem, SC=spinal cord; PI=post-inoculation.
doi:10.1371/journal.pntd.0001567.t004
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satellitosis, necrosis, and degeneration. Gliosis was marked in the
regions of intense inflammation and the overlying meninges
typically contained small to moderate numbers of lymphocytes
and macrophages (Fig. 3, panel F). Spinal cord sections from these
three animals displayed similar lesions; however, the lesions in one
Figure 3. Representative rVSV-wt histology showing lesions in all neural tissue examined. (A) Frontal cortex (106) section with severe
encephalitic changes including perivascular lymphohistocytic cuffs (arrows) and aggregates of lymphocytes in the neuroparenchyma (*). (B) Frontal
cortex (106) section with perivascular cuff of lymphocytes and histocytes (arrow). (C) Cerebellum (106) section with aggregates of lymphocytes in
the parenchyma (arrows) admixed with increased numbers of reactive glial cells. (D) Spinal cord (106) section with gliosis admixed with regions of
perivascular inflammation (arrows). (E) Frontal cortex (406) section depicting large numbers of perivascular lymphocytes and histocytes infiltrating
into the adjacent gray matter. (F) Basal ganglia (406) section depicting large numbers of lymphocytes and histocytes both around a meningeal vessel
and invading into the adjacent tissue.
doi:10.1371/journal.pntd.0001567.g003
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scattered neuronal satellitosis (Table 4).
The seven animals that received rVSV-ZEBOV-GP had a
variety of mild histologic changes. One animal (363-09) lacked
parenchymal lesions in the brain and spinal cord (Table 4), while 6
of the 7 animals (352-09, 354-09, 357-09, 358-09, 360-09, 361-09)
had rare, focal areas of meningeal inflammation in various
cerebral sections (Fig. 4, Table 4). Only one animal (357-09) had a
small focal area of meningeal inflammation in the cerebellum.
There were no spinal cord lesions in any of the rVSV-ZEBOV-GP
animals examined (Fig. 4 and 5, Table 4).
The macaques that received the rVSV-MARV-GP IT inocu-
lation had varied histology. Two animals (57-09, 61-09) did not
have any histologic lesions present in the brain and spinal cord
Figure 4. Representative rVSV-ZEBOV-GP histology. (A and B) Frontal cortex (106) sections with no lesions. (C) Cerebellum (106) section with
no lesions. (D) Spinal cord (106) section with no lesions. (E) Frontal cortex (406) section with a mild perivascular cuff of lymphocytes. (F) Occipital
cortex (406) section with a mild perivascular cuff of lymphocytes.
doi:10.1371/journal.pntd.0001567.g004
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had mild lesions in the cortex consisting of small perivascular cuffs
of lymphocytes and rare macrophages (Table 4). Another animal
(364-09) had similar perivascular infiltrates also present in the
brainstem (Table 4). Multifocal meningeal, perivascular aggregates
of lymphocytes were also seen in two animals (356-09, 364-09)
(Fig. 6). Lastly, one animal (355-09) had a focal tract of necrosis in
the caudal basal ganglia/proximal thalamus that corresponded to
the injection site. No brain lesions were observed away from the
injection site in any of the rVSV-MARV-GP IT animals (Table 4).
Figure 5 represents the average of the combined left and right
hemispherescores from Table 4 for eachgroup in the study in order
to compare the combined histological scores from neural tissues.
Overall, comparisons between the rVSV-wt group and the rVSV-
ZEBOV-GP or rVSV-MARV-GP groups show that the difference
between scores were significant (p=0.0016 and p=0.0019
respectively). From these data the rVSV filovirus GP vaccines
appear to have no substantial NV in cynomolgus macaques.
Discussion
More than seven years ago, rVSV vectors expressing foreign
GPs from EBOV and MARV were developed and characterized
[34]. These rVSV vaccine vectors were subsequently used in
cynomolgus and rhesus macaques to assess their ability to protect
animals from lethal challenge with ZEBOV, SEBOV, CIEBOV,
and MARV, respectively [8,9,11,12,18,35]. While the results of
these initial experiments were promising, VSV and rVSV have
displayed NV in experimental settings using rodents
[41,42,43,44,45,46,47,48,62] and in cynomolgus and rhesus
macaques that were inoculated intracerebrally [49,59]. The NV
seen in these experimental settings raised the question about the
safety and NV of the replication-competent rVSV filovirus GP
vaccines. To address this question we compared vehicle control,
rVSV-wt, rVSV-ZEBOV-GP, and rVSV-MARV-GP since these
vaccine vectors are replication-competent. We modeled our NV
test on the platform and scoring system employed for the yellow
fever virus vaccine [55] and rVSV HIV vaccine vectors [59].
Contrary to the rVSV-wt cohort, none of the macaques in
either the vehicle control group or the two filovirus vaccine groups
displayed clinical neurological abnormalities (Table 1). This
pattern was also seen when comparing the amount of detectable
rVSV RNA in the macaques as two rVSV-wt animals (56-09, 67-
01) had the most significant amount of rVSV and rVSV RNA
detected in the neural tissue (Table 2). In particular, it was
interesting that one of these animals (56-09) also had rVSV and
rVSV RNA detectable in the right frontal cortex, considering that
the experimental inoculation was in the left hemisphere thalamus
suggesting spread of rVSV-wt through the neural tissues.
Histopathologic analysis confirmed that the rVSV-wt virus is
NV in cynomolgus macaques causing severe encephalitis when
inoculated IT. All three animals in this cohort displayed varying
degrees of inflammation and neurodegeneration in the brain and
spinal cord sections evaluated with one of the macaques (56-09)
having the most severe scores throughout the neural tissue
(Table 4) which correlated with the detectable amounts of rVSV
RNA in neural tissue (Table 2). None of the animals in the rVSV
filovirus GP vaccine or vehicle control groups showed any
evidence of neurodegeneration or neuroinflammation. Animals
in both rVSV filovirus GP vaccine groups had occasional
perivascular lymphocytes and meningeal infiltrates primarily in
the frontal cortex and thalamus (Fig. 6, Table 4); however, there
was no spread into the adjacent parenchyma and no evidence of
neurodegeneration, satellitosis, or gliosis. It is also interesting to
note that there were no lesions seen in the spinal cord for the two
rVSV filovirus GP vaccine groups whereas there were lesions seen
in the rVSV HIV vaccine IT-inoculated macaques in a previous
study [59]. The difference between the lesions seen for rVSV HIV
vaccine IT-inoculated macaques and our study could be the fact
that the HIV vaccines still contain the VSV G protein whereas the
rVSV filovirus GP vaccines lack the VSV G protein. Also, as
described by Johnson et al., this observation could have resulted
from contamination of the cerebrospinal fluid while performing
the IT inoculation. This could be the case, although we observed
lesions in the spinal cord for all macaques in the rVSV-wt group
including one animal (362-09) which showed no major clinical
neurologic disease symptoms and had no detectable rVSV RNA at
day 21 in the neural tissues. Taken together, the histological lesion
scores confirm that neither rVSV-ZEBOV-GP nor rVSV-MARV-
GP is significantly NV and neither causes significant neuropa-
thology in the cynomolgus macaque when inoculated IT as
compared to clarified Vero cell culture fluid and rVSV-wt. It is
interesting to note that the very mild inflammation seen in some of
the vaccine cohorts in our study are far below that which is
Figure 5. Combined histological scores of neural tissue. Graph displaying the mean histological values of the neural tissue from left and right
hemisphere for the frontal cortex (FC), basal ganglia (BG), thalamus (TH), occipital cortex (OC), and cerebellum/brainstem (CB/BS), plus scores from
the spinal cord (SC). Error bars, standard deviation. VC=vehicle control.
doi:10.1371/journal.pntd.0001567.g005
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recently reviewed [63]. Although the neurotropic differences of
viruses are difficult to compare our findings that the rVSV filovirus
GP vaccines are similar to and even further attenuated for NV
than a widely used vaccine are encouraging.
Recovery of detectable rVSV RNA from swabs seemed to
correlate with small lesions seen in some of the rVSV-ZEBOV-GP
animals (357-09, small lesion in meninges of cerebellum 358-09,
small lesion in meninges of right basal ganglia), whereas one
animal (352-09) had no detectable lesions (Table 4). Low amounts
Figure 6. Representative rVSV-MARV-GP histology. (A) Frontal cortex (106) section from 59-09 that had a small perivascular cuff of
lymphocytes. (B) Frontal cortex (106) section with no lesions. (C) Cerebellum (106) section with no lesions. (D) Spinal cord (106) section with no
lesions. (E) Frontal cortex (406) section with a mild perivascular cuff of lymphocytes. (F) Frontal cortex (406) section with a scant perivascular cuff of
lymphocytes.
doi:10.1371/journal.pntd.0001567.g006
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animal (358-09), despite the detection of rVSV RNA at this site
there were no spinal cord lesions in this animal or in any other
neural tissue sampled from this animal. These observations
combined with the swab data for this animal suggests the rVSV-
ZEBOV-GP virus may have moved beyond the neural tissue from
the site of inoculation. This thought is interesting considering
EBOV and MARV initially target dendritic cells and macrophages
in vivo [64,65]. The fact that these rVSV vectors express filovirus
GP and have the protein on the virion surface, which would target
the vectors to dendritic cells and macrophages, could explain why
in a few cases they were detected in areas outside of the neural
tissue perhaps targeting dendritic cells and macrophages that
appeared at the IT inoculation sites which then migrated to LN
(Table 2) or other sites (Table 3) where the RNA was able to be
isolated. In fact, only the day 2 nasal swab from 357-09 was
positive for virus isolation (Table 3) with low levels of virus.
Considering the lack of shedding of these vaccines in the previous
studies this was interesting. There are a few possibilities as to why
virus may have been detected in this study: transfer of virus along
neurons through the olfactory bulb to the olfactory neurons, or the
fact that the nasal swab procedure sometimes results in minor
bleeding regardless of how gentle the nares are swabbed, which
could have picked up a low level viremia not picked up by qRT-
PCR.
The lack of NV in the rVSV filovirus GP vaccine vectors when
compared to rVSV-wt is encouraging considering that the
vaccines are not attenuated through mutation of known virulence
markers such as methionine 51 of the VSV M protein [66,67].
These results are similar to studies with VSV vectors expressing
influenza hemagglutinin (HA) protein which are completely
attenuated for pathogenesis in the mouse model [24] when
compared to rVSV-wt. These study results should perhaps not be
surprising considering the glycoprotein(s) of a virus generally
contributes to cell tropism, and when compared to VSV, the
filoviruses and influenza virus do not show a neural tropism. The
deletion of VSV G and replacement of this protein with
glycoproteins from foreign viruses that do not have a neural
tropism would suggest the rVSV-(foreign glycoprotein) would not
be NV. However, even though glycoproteins contribute to cell
tropism other viral factors that also contribute cannot be ruled out,
which is why NV testing is important when evaluating vaccine
safety. The clinical, histological, and virus replication data from
this study indicate that the rVSV-ZEBOV-GP and rVSV-MARV-
GP vectors lack the NV properties of the rVSV-wt vector.
In addition to this NV study, the rVSV-ZEBOV-GP vector has
been safety tested in two animal models with defective immune
systems, NOD-SCID mice [68] and SHIV-infected rhesus
monkeys [35]. Upon immunization, no evidence of overt illness
was noted in any of these immunocompromised animals. Also, the
rVSV-ZEBOV-GP vector was recently used to treat a laboratory
worker after a recent laboratory accident without any major
complications [40]. We have previously shown that rVSV filovirus
GP vectors have efficacy as preventive vaccines and postexposure
treatments and have promising safety profiles. These data together
with findings from our current NV study suggest that the rVSV
filovirus GP vaccine system is ready for advanced development for
human use.
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